目的：探讨支气管肺泡灌洗(bronchoalveolar lavage，BAL)联合长期小剂量阿奇霉素治疗支气管扩张症患者的临床效果及对患者肺功能的影响作用。方法：回顾性分析本院2012年2月至2014年12月治疗的83例支气管扩张症患者，其中44例患者采用常规治疗联合BAL+阿奇霉素(250 mg/次，1周2次，连续治疗6个月)作为观察组，对照组39例患者仅采取常规治疗+BAL疗法，对比2组的临床效果及肺功能变化。结果：治疗前，急性期结束时观察组和对照组的hs-CRP、WBC水平差异无统计学意义(P>0.05)；经过6个月治疗，观察组患者血清hs-CRP水较对照组低(P<0.05)；治疗6个月后，观察组的痰液MD、MP评分及痰液量显著低于对照组(P<0.05)；急性期结束时，两组患者的PEF、FEV1、FVE1/pred测定结果差异不具有统计学差异(P>0.05)；经过6个月治疗，观察组的FEV1、FVE1/pred测定值明显的优于对照组患者(P<0.05)。结论：BAL联合长期小剂量阿奇霉素治疗支气管扩张症患者临床效果更好，对患者的肺功能改善效果更佳。
Effects of bronchoalveolar lavage combined with long term low dose azithromycin on the treatment of patients with bronchial dilation and pulmonary function
Objective: To discuss the clinical effect of bronchoalveolar lavage (BAL) combined with long term low dose azithromycin in the treatment of patients with bronchial dilation and its effect on lung function. Methods: A retrospective analysis of 83 cases with bronchiectasis treated in our hospital from February 2012 to December 2014, 44 patients were treated with conventional therapy combined with BAL and azithromycin (250 mg/times, twice a week, for 6 consecutive months) as the observation group, 39 patients in the control group only taking conventional therapy + BAL therapy, compared the clinical effect and lung function between the two groups. Results: Before treatment, at the end of the acute phase of the observation group and control group, the level of hs-CRP and WBC has no significant difference (P>0.05); after 6-month treatment, the level of serum hs-CRP in the observation group was significantly lower than the control group (P<0.05), and the sputum MD, MP score and sputum volume in the observation group was also significantly lower than those in the control group (P<0.05); at the end of the acute phase, the difference of PEF, FEV1, FVE1/pred measurement between the two groups was not statistically significant (P>0.05); after 6-month treatment, FEV1 and FVE1/pred in the observation group are significantly better than those in the control group (P<0.05). Conclusion: BAL combining long-term low-dose azithromycin has better clinical effect on the treatment of bronchiectasis, and also improves lung function better.